Background Patisiran, an investigational RNA interference therapeutic agent, specifically
inhibits hepatic synthesis of transthyretin. Methods In this phase 3 trial, we randomly assigned …

Background Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide
variants in the gene encoding transthyretin (TTR) that induce transthyretin misfolding and …

Background: Revision of the guidelines on the use of skin biopsy in the diagnosis of peripheral
neuropathy, published in 2005, has become appropriate owing to publication of more …

We sought to develop and validate a standardized cutaneous nerve regeneration model
and to define the rate of epidermal nerve fibre (ENF) regeneration first in healthy control …

Valid and reliable biomarkers can play an important role in clinical trials as indicators of
biological or pathogenic processes or as a signal of treatment response. Currently, there are no …

Patients with complaints of numbness, tingling, and dysesthesias in the toes and feet are
frequently referred to neurologists. Often, the only objective evidence for peripheral nerve …

Objectives: To characterize the natural history of oxaliplatin-associated neuropathy (ON)
and determine whether intraepidermal nerve fiber density (IENFD) is a sensitive measure of …

Today, skin biopsies can play an important role in the diagnosis of peripheral nerve
disorders and have yielded another diagnostic tool for the neurologist. One of the commonly …

Background The study objective was to assess the effect of vutrisiran, an RNA interference
therapeutic that reduces transthyretin (TTR) production, in patients with hereditary …

Objective: To determine the prevalence of different forms of peripheral neuropathy in
patients with restless legs syndrome (RLS) and correlate the findings with other clinical …